梯瓦制药（TEVA）今日盘中股价大涨6.47%，引发市场广泛关注。
消息面上，公司最新发布的第二季度财报显示，营收达到41.42亿美元，超出市场预期的40.47亿美元，成为支撑股价走高的核心驱动力。尽管调整后每股收益仅为0.02美元，大幅低于分析师预期的0.25美元，但营收端的超预期表现显然更受市场重视。
此外，公司近期在生物类似药及创新管线领域持续取得进展，包括Ocrevus生物类似药的全球授权、Eylea生物类似药在欧洲的上市推进，以及ecopipam新药申请的提交等多项利好，也从侧面增强了市场对公司长期增长前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.